机构：[1]School of Chinese Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong,[2]Shenzhen Institute of Research and Innovation, University of Hong Kong, Shenzhen,[3]College of Pharmacy, Chengdu University of Chinese Medicine, Chengdu,[4]Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,[5]Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou,大德路总院乳腺科大德路总院乳腺科广东省中医院[6]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, People’s Republic of China
Isoliquiritigenin (ISL), a natural anti-breast cancer dietary compound, has poor delivery characteristics and low bioavailability. In order to promote the therapeutic outcome of ISL, a tumor-targeting lipid-polymer hybrid nanoparticle (NP) system modified by tumor-homing iRGD peptides has been developed. The hybrid NPs were prepared by a modified single-step nanoprecipitation method to encapsulate ISL. iRGD peptides were anchored on the surface by a postinsertion method (ISL-iRGD NPs). The stable lipid-polymer structure of ISL-iRGD NPs, with high encapsulation and loading efficiency, was confirmed. Compared to free ISL and non-iRGD-modified counterparts, ISL-iRGD NPs showed higher cytotoxicity and cell apoptosis against the different type of breast cancer cells. This was attributable to higher cellular accumulation mediated by the iRGD-integrin recognition and the nanoscale effect. More importantly, based on the active tumor-tissue accumulation by iRGD peptides and the prolonged in vivo circulation by the stealth nanostructure, ISL-iRGD NPs displayed higher tumor-growth inhibition efficiency in 4T1-bearing breast-tumor mouse models. Therefore, the constructed iRGD modified lipid-polymer hybrid NPs would provide a promising drug-delivery strategy to improve ISL in anti-breast cancer efficacy.
基金：
Seed Funding in HKU (201511160021 and 201409160015) and Chinese National Natural Science Foundation (81573663). The project was also funded by the Talent Training Program, 2011 Cooperation Program of Chengdu University of Traditional Chinese Medicine. The abstract of this paper was presented at the 15th World Congress on Cancer Therapy, Biomarkers, and Clinical Research, December 5-7, 2016 in Philadelphia, PA.
第一作者机构：[1]School of Chinese Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong,[2]Shenzhen Institute of Research and Innovation, University of Hong Kong, Shenzhen,[3]College of Pharmacy, Chengdu University of Chinese Medicine, Chengdu,
通讯作者：
通讯机构：[1]School of Chinese Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong,[2]Shenzhen Institute of Research and Innovation, University of Hong Kong, Shenzhen,[3]College of Pharmacy, Chengdu University of Chinese Medicine, Chengdu,[*1]School of Chinese Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong 999077
推荐引用方式(GB/T 7714)：
Gao Fei,Zhang Jinming,Fu Chaomei,et al.iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability[J].INTERNATIONAL JOURNAL OF NANOMEDICINE.2017,12:4147-4162.doi:10.2147/IJN.S134148.
APA：
Gao, Fei,Zhang, Jinming,Fu, Chaomei,Xie, Xiaoming,Peng, Fu...&Chen, Jianping.(2017).iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.INTERNATIONAL JOURNAL OF NANOMEDICINE,12,
MLA：
Gao, Fei,et al."iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability".INTERNATIONAL JOURNAL OF NANOMEDICINE 12.(2017):4147-4162
工程技术